Browsing Conditions, Lifestyle Factors & Interventions by Subject "Immunotherapy"
Now showing items 1-4 of 4
-
Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)
(2019-06)Background: Evidence is conflicting about a causal role of inflammation in psychosis and, specifically, regarding antibodies binding to neuronal membrane targets, especially N-methyl-D-aspartate receptors. NMDAR, LGI1 and ... -
Mania as a possible complication of immunotherapy
(2020-02)Immunotherapy is still a relatively new cancer therapy and this article serves as a reminder to psychiatric teams to consider immunotherapy as a possible factor in psychiatric presentations. Here, the authors present the ... -
The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data
(2019-03)Early immunotherapy administration improves outcomes in patients with N-methyl-D-aspartate receptor (NMDAR)-antibody encephalitis. As most patients with NMDAR-antibody encephalitis present to psychiatrists, the psychopathology ... -
Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1)
(2018-06-11)The main finding of the SINAPPS1 study is that immunotherapy can be delivered rapidly and safely to people with acute psychosis within an acute hospital setting. The treatments were tolerated and there were no cases of ...